Funding drought forces alternative protein companies to combine or close

INTRODUCTION

At least 82 alternative protein businesses have changed hands, merged, entered insolvency or closed since September 2024, according to Green Queen. The tally matters because capital now favours proven demand, efficient production and credible margins.

Green Queen counted 54 such cases in the latest 12-month period, a 35% rise against the preceding year. Acquisitions represented 65% of those cases, while insolvencies, discontinued brands and shutdowns made up the rest. The retreat follows a sharp fall in investment and a slower path to mass demand than many companies expected. Plant-based brands account for most recorded cases, but cultivated meat and fermentation companies face their own pressures from scale, regulation and production costs. The Good Food Institute identifies growth factors as one stubborn expense in cultivated production. These signalling proteins cost much to make and remain active for only a short time. Evidence presented at ProVeg International’s New Food Conference adds the demand and supply-chain view. Consumers value products that fit ordinary routines, while farmers need dependable buyers before banks can finance unfamiliar protein crops. The evidence points to a market correction rather than one simple failure. Money, technology, retail practice and customer need must now align. Few businesses can afford to solve only one part.

CORE FINDING

Green Queen’s analysis finds that the current shakeout follows the investment slowdown that began around 2023. Deniz Ficicioglu, co-founder of BettaF!sh, a seafood alternative maker, told Green Queen that many young companies had enough cash for 18 to 24 months. That timetable now leaves businesses needing fresh capital, profit or a buyer. Yoni Glickman of PeakBridge, a food technology investor, offered a similar diagnosis. He said companies financed in 2021 and 2022 have reached the limits of their cash. Christian Nagel of Earlybird, a venture capital investor, said adoption, factory scale and margins developed more slowly than investors had assumed. These are assessments from market participants, not audited explanations for every closure. Yet the deal count supports their broad conclusion. A funding model built around repeated capital raises has met investors who now require commercial proof. Acquisition becomes the least damaging option when that proof arrives too late.

FUNDING

Investment across alternative protein fell to $881m in 2025, according to Green Queen, taking the annual total below $1bn for the first time since 2018. Fermentation funding dropped by 43.5%, Green Queen reported. Cultivated meat companies raised more during 2021 than across the following four years combined, according to the publication’s analysis. Funding for plant-based companies rose by 31.5% against 2024, but that comparison includes a $100m debt round from Beyond Meat, a meat alternative producer. Green Queen calculated that the increase would have been only 2% without that borrowing. The distinction matters. Debt supplied to an established listed company says little about investors’ willingness to fund early technical risk. The headline rise in one segment therefore masks a broad scarcity of equity capital. Buyers with cash gain bargaining power, while companies with factories, staff and regulatory work to fund lose time.

The squeeze extends beyond food technology. US venture fundraising in the first quarter of 2026 stood 70% below its 2022 peak, according to PitchBook analysis cited by Green Queen. Artificial intelligence businesses captured 61% of worldwide venture investment in 2025, the publication reported. Steve Simitzis of Replicator VC, an early-stage investment firm, linked the change in food funding to higher US interest rates and the failures of Silicon Valley Bank and First Republic. He estimated that an initial runway of 18 to 24 months, followed by bridge funding lasting 12 to 18 months, would push many failures into 2025 and 2026. His timing is an investor’s model, not a measured rule. Even so, it explains why closures can continue well after funding conditions first worsen. Cost cuts and strategic changes delay failure. They do not create solvent customers.

BUYERS

Livekindly Collective, a brand holding company, shows the buyer’s case. The owner of Oumph, Fry’s and Like recorded its first profitable month in 2025 and acquired Greenforce, a German food company, in July 2026, according to Green Queen. Chief executive David Suarez told the publication that retailers want suppliers with scale, dependable service and category knowledge. He presented acquisitions as a means to combine operations and capabilities rather than collect brands. That is a company claim and should be treated as such. Greater size can reduce duplicate overhead and strengthen negotiations with manufacturers or retailers. It can also preserve products that would otherwise disappear. The counter-argument is that fewer owners may narrow competition and consumer choice. Green Queen provides no pricing, shelf-space or product-range data with which to test either outcome. Profit in a single month also offers thin evidence of lasting financial health.

BettaF!sh followed a related route when Bayou Best Foods, a US food company, acquired it in June 2026, according to Green Queen. Ficicioglu said the discussions began as a possible collaboration before both sides chose a sale. She described the assets as complementary. BettaF!sh brought knowledge of European seaweed, processing methods, ingredients and branded products. Bayou Best Foods contributed US food-service experience, manufacturing and commercial operations. The rationale differs from a rescue based only on cost cutting. It joins market access and production skills that each side lacked alone. The source gives no purchase price, revenue, profitability or integration targets. Evidence that the combination will work is therefore absent. The deal still illustrates why founders may prefer a strategic owner to another short financing round. A buyer can supply routes to customers as well as cash.

SEGMENTS

Plant-based businesses represented 72% of the deals, insolvencies and closures recorded since July 2025, according to Green Queen. Cultivated protein accounted for 15%, while fermentation represented 11%. Suarez argued that the first category appears more often because it has more companies, established sales, retail listings and manufacturing assets. Those features make businesses both more exposed to weak consumer sales and easier to acquire. Nagel added that crowded categories and limited product distinction raise the odds of combinations or exits. Simitzis offered a sharper interpretation. He said consumer-facing models suffered more than business-to-business ingredient suppliers. He pointed to weak sentiment around meat substitutes and the fall in Beyond Meat’s shares as signs of that pressure. The available figures establish the difference in deal shares. They do not establish whether maturity, business model or consumer resistance contributes most.

Cultivated and fermentation companies face a different test. Glickman told Green Queen that successful synthetic biology fundraisers increasingly show low-capital routes to scale, attractive unit economics and regulatory clearance. Nagel said investors also seek proprietary technology, defensible intellectual property and a believable route to profit. Simitzis argued that proof of scale now counts only as an entry condition. In his view, companies also need a customer with an urgent problem and money to solve it. He identified costly whey, food inflation, demand for protein linked to GLP-1 medicines and pressure on livestock as possible sources of demand. These remain an investor’s propositions rather than demonstrated markets in the supplied evidence. The underlying standard is clearer. Technical progress without a paying customer no longer supports the valuations that abundant capital once allowed.

CULTIVATED COSTS

The Good Food Institute, an alternative protein nonprofit, identifies growth factors as a persistent barrier to cheaper cultivated meat. These small proteins tell cells how to grow and develop. They have historically raised culture-media costs because production is expensive and their useful life is short, according to the institute. Its August 13 virtual seminar featured Cameron Semper of the University of Calgary, who studies genome mining and protein engineering as possible ways to reduce that burden. Semper’s research group also uses microbial cell factories in alternative protein work, according to the event description. The source reports no cost reduction, production yield or commercial trial. It therefore describes a research route, not a solved economic problem. Consolidation cannot remove this constraint by itself. A larger owner may finance research or spread costs across more activity, but the supplied sources provide no evidence that merged cultivated companies have achieved that result.

Artificial intelligence may help with forecasting, product design and operations, Suarez told Green Queen. Simitzis went further, arguing that computational tools could shorten development and lower the capital needed before commercial launch. Nagel rejected the notion that artificial intelligence makes other fields uninvestable. He said proprietary solutions with sound economics can still attract funds, although investors have raised the threshold. The disagreement concerns degree rather than direction. Software may make experiments or operations cheaper. It cannot replace regulatory permission, factory performance or repeat purchases. Suarez made that limit explicit by saying technology cannot stand in for a viable business model. None of the supplied sources quantifies savings from these tools in cultivated or fermentation production. Claims that they can repair sector economics therefore remain untested here.

DEMAND

Evidence from Berlin puts ordinary shopping behaviour ahead of technical novelty. More than 260 people from 17 countries attended ProVeg International’s New Food Conference on August 25, according to vegconomist. More than 100 additional industry representatives joined related events, the publication reported. Denise Blömers of YouGov told the conference that buyers reward practical relevance. YouGov research cited by vegconomist found that 75% of consumers value fitting dietary choices easily into daily routines. Miriam Schroer of Lidl Germany said shoppers want substitute products placed beside the familiar animal versions in supermarkets. She also advised companies to stop using the word “alternatives” in consumer messages. These views suggest that familiarity may sell better than novelty. They do not show that a change in labels or shelf position will reverse weak demand. The source supplies no sales experiment to test the advice.

Madre Brava calculated that Germany needs about 600,000 more households buying alternative proteins regularly before the category reaches the mass market, according to vegconomist. The publication also reported that retailer own-label products currently lead category growth. Price matters, but flexitarian shoppers also consider clear labels and confidence in ingredients, according to the conference account. These findings complicate the claim that consolidation alone produces stronger consumer businesses. A larger owner can supply private-label ranges and negotiate shelf placement. It still must meet expectations on cost, composition and convenience. Daniel Anthes told the conference that not every plant-based item is healthy by default. He called for credible discussion of long-term health and prevention rather than narrow immediate benefits. That warning matters because nutrition claims may attract scrutiny when companies reposition products for health-conscious customers.

NUTRITION

Anna-Lena Klapp of ProVeg International said GLP-1 weight-loss medicines are shaping product development in Europe and elsewhere, according to vegconomist. Lower food intake gives consumers fewer opportunities to obtain required nutrients, she argued. Manufacturers are responding by paying closer attention to formulation. The conference discussion focused on digestible protein and dietary fibre, which the publication noted occurs only in food derived from plants. Morgan Griffiths of Lumina Intelligence described these products as a possible support for people using GLP-1 therapies, provided manufacturers move quickly. Devika Suresh of the ProVeg Incubator pointed to biomass fermentation, traditional fermentation and use of byproducts as approaches with recognisable links to existing food. These are commercial positions offered at an industry event. The source gives no clinical outcomes or sales figures tying such formulations to medicine users. Companies should not mistake a plausible customer need for proven product-market fit, the very error investors now criticise.

SUPPLY CHAINS

Domestic production also presents an economic mismatch. Germany imports 90% of the legumes used for human food, while animal feed takes 81% of the country’s own output, Maximo Graesse of ProVeg told the Berlin conference, according to vegconomist. Anne Lerche of the Alliance for Biosolutions described protein resilience as an industrial policy matter. Anders Klöcker of the Danish Agriculture and Food Council said farmers must take part in national protein planning. Patricia Rishi Sundstrom of the Farm Adaptation Network identified finance as the practical barrier. Banks cannot easily price loans for crops without established markets, she said. Multi-year purchasing commitments can turn uncertainty into a risk that lenders can calculate. This mechanism connects consolidation with farm supply. A larger food group may be better able to promise long contracts. Yet the source names no completed contract, loan value or resulting increase in cultivation.

PRODUCT ROUTES

Hybrid foods offer another response to weak demand. Products mixing animal and plant proteins are already common in the Netherlands, according to vegconomist. Conference participants argued that these foods can compete on taste, nutrition and price while reaching people who reject fully meat-free products. Christiane Seidel of the Federation of German Consumer Organisations backed hybrids as a legitimate bridge rather than a contest between two camps. The approach may broaden the customer base, but it also changes the proposition that many alternative protein companies originally sold. Green Queen’s account supports such adaptation. Ficicioglu said businesses unable to alter their model, secure more money, reach profit or find a partner now face difficult choices. Hybrids, ingredient sales and moves into adjacent industries may keep technology in use. The supplied sources give no figures showing which pivot offers the best survival rate.

OUTLOOK

Green Queen recorded seven acquisitions or liquidations from June to early July 2026. Suarez expects further combinations because retailers have limited shelf space and demand consistent quality and value. Glickman argued that combining companies can reduce duplicated operating costs and make better use of capital. Nagel called the process a normal correction in which stronger technologies, teams and models survive. Simitzis disputed the need to label consolidation either healthy or harmful. He said failed companies can still transfer staff and intellectual property elsewhere, while some businesses continue in a depleted state. This is the clearest disagreement among the sources. Buyers and their investors frame combination as maturity. Simitzis treats it as one possible result of company failure. The evidence supports continued pressure, but not the claim that every transaction improves the sector.

CONCLUSION

Consolidation deserves credit only where it produces lower costs, dependable supply and products that customers repeatedly buy. Nagel says the pace will depend on financing conditions and consumer demand, while cultivated producers must also show that work on costly inputs such as growth factors can move beyond the laboratory.